-
Mashup Score: 2Imlunestrant With or Without Abemaciclib Boosts PFS in ESR1+, ER+/HER2– Advanced Breast Cancer - 3 hour(s) ago
Imlunestrant with or without abemaciclib improved PFS in select patients with ER-positive, HER2-negative advanced breast cancer after endocrine therapy.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
Adjuvant olaparib maintained an efficacy benefit vs placebo in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Adjuvant Olaparib Maintains iDFS Benefit in BRCA1/2+, HER2– Breast Cancer. @judy.garber5 @danafarber @sabcssanantonio #SABCS24 #bcsm https://t.co/2TkKDsMaRj
-
-
Mashup Score: 2Neoadjuvant Patritumab Deruxtecan ± Letrozole Shows Efficacy in High-Risk HR+/HER2– Breast Cancer - 4 hour(s) ago
Neoadjuvant patritumab deruxtecan with or without letrozole produced pathologic complete responses in high-risk, HR-positive/HER2-negative breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Neoadjuvant Patritumab Deruxtecan ± Letrozole Shows Efficacy in High-Risk HR+/HER2– Breast Cancer @SABCSSanAntonio #SABCS24 #bcsm #oncology https://t.co/4FxjmTgZTk
-
-
Mashup Score: 2
SHR-A1811 monotherapy demonstrated high clinical activity and was well tolerated in patients with HER2-positive breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
SHR-A1811 Shows Initial Antitumor Activity, Tolerability in HER2+ Breast Cancer @SABCSSanAntonio #SABCS24 #bcsm #oncology https://t.co/uW4X2ENzvT
-
-
Mashup Score: 0Elacestrant Plus Abemaciclib Shows Efficacy in ER+/HER2– Advanced or Metastatic Breast Cancer - 4 hour(s) ago
Elacestrant plus abemaciclib demonstrated clinically important efficacy in ER-positive/HER2-negative advanced or metastatic breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Elacestrant Plus Abemaciclib Shows Efficacy in ER+/HER2– Advanced or Metastatic Breast Cancer @hoperugo @UCSFCancer @SABCSSanAntonio #SABCS24 #bcsm #medtwitter #oncology https://t.co/sI4HOKcBUC
-
-
Mashup Score: 1Cilta-Cel Leads to 100% MRD-Negativity Rate in High-Risk Smoldering Multiple Myeloma - 4 hour(s) ago
Cilta-cel without induction therapy in high-risk smoldering myeloma marked the first study of CAR T-cell therapy in a precursor cancer setting.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Cilta-Cel Leads to 100% MRD-Negativity Rate in High-Risk Smoldering Multiple Myeloma @DanaFarber @ASH_hematology #ASH24 #mmsm #oncology https://t.co/7DH4mYLH7M
-
-
Mashup Score: 3
Hope S. Rugo, MD, FASCO, discusses updated safety findings from the ELEVATE trial of elacestrant-based combinations in ER+/HER2– metastatic breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
WATCH: Hope S. Rugo, MD, FASCO, discusses updated safety findings from the ELEVATE trial of elacestrant-based combinations in ER+/HER2– metastatic breast cancer. @hoperugo @UCSFCancer @SABCSSanAntonio #SABCS24 #bcsm #oncology https://t.co/YEO9Q5wljE
-
-
Mashup Score: 1
Risk-reducing surgery improved survival outcomes in younger patients with breast cancer and a germline BRCA mutation.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Risk-Reducing Surgery Improves Survival Outcomes in Younger BRCA+ Breast Cancer @SABCSSanAntonio #SABCS24 #bcsm #oncology https://t.co/CG30ePy3Rp
-
-
Mashup Score: 1T-DXd Improves PFS Irrespective of Time to Progression, Type of Endocrine Resistance in HER2-Low/-Ultralow Metastatic Breast Cancer - 6 hour(s) ago
T-DXd improved PFS vs treatment of physician’s choice in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
T-DXd Improves PFS Irrespective of Time to Progression, Type of Endocrine Resistance in HER2-Low/-Ultralow Metastatic Breast Cancer. @sabcssanantonio @dradityabardia @uclajccc #SABCS24 #bcsm https://t.co/d9LeszKw9Z
-
-
Mashup Score: 0Elacestrant Shows Tolerability in Combination With CDK4/6, PI3K Inhibitors in Advanced ER+ Breast Cancer - 6 hour(s) ago
Elacestrant was partnered with multiple targeted agents across varying dose levels and schedules for patients with estrogen receptor–positive advanced breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Elacestrant Shows Tolerability in Combination With CDK4/6, PI3K Inhibitors in Advanced ER+ Breast Cancer @hoperugo @UCSFCancer @SABCSSanAntonio #SABCS24 #bcsm #medtwitter #oncology https://t.co/oWEzAAl5vu
-
Imlunestrant With or Without Abemaciclib Boosts PFS in ESR1+, ER+/HER2– Advanced Breast Cancer @jhaveri_komal @MSKCancerCenter @SABCSSanAntonio #SABCS24 #bcsm #medtwitter #oncology https://t.co/bhmMdWrIa1